TY - JOUR
T1 - Proceedings From the First International Workshop at Sidra Medicine
T2 - “Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development”, 15th–16th February 2019, Doha, Qatar
AU - The EICCI Faculty Group
AU - Guerrouahen, Bella
AU - Elnaggar, Muhammad
AU - Al-Mohannadi, Anjud
AU - Kizhakayil, Dhanya
AU - Bonini, Chiara
AU - Benjamin, Reuben
AU - Brentjens, Renier
AU - Buchholz, Christian J.
AU - Casorati, Giulia
AU - Ferrone, Soldano
AU - Locke, Frederick L.
AU - Martin, Francisco
AU - Schambach, Axel
AU - Turtle, Cameron
AU - Veys, Paul
AU - van der Vliet, Hans J.
AU - Maccalli, Cristina
AU - Benabdellah, Karim
AU - Bos, Tomas
AU - Cugno, Chiara
AU - Johnston, Ian
AU - Mohamed, Ali
AU - Ponterio, Eleonora
AU - Abu Rasheed, Hadi Mohamad
AU - Roelands, Jessica
AU - Taha, Ruba Y.
N1 - Funding Information:
We would like to acknowledge the contributions of the EICCI scientific committee, Drs. Christof von Kalle, Sara Deola, Catherine Cole, (Sidra Medicine), Drs. Alexander Knuth, Gianfranco Pittari, Javid Gaziev; Said Dermime, (NCCCR, HMC); the organizing committee, Ms. Nelly EL Mistekawy, Maricris Salud, Nevin Amin, Hamda Zain Al Abdeen (Sidra Medicine); Prof. Matthew Porteus (Stanford University, San Francisco, CA, USA) as faculty member of the workshop and all the chairs of the workshop’s sessions. This workshop was organized with the partnership of Hamad Medical Corporation and Qatar Cancer Society. We would like to recognize Miltenyi Biotech (Germany), Beckman Coulter/Medtech (Germany/Qatar), Therumo BCT (Germany) and Ideal Medical Solution (Qatar) for cash or in kind supports to the conference.
Funding Information:
The EICCI workshop was funded by the Qatar National Research Fund (QNRF)-Conference Workshop Sponsorship Program grant CWSP15-W-0911-18001 (Doha, Qatar). CBo received funding from AIRC (Ig 18458) and AIRC 5 per Mille, Rif. 22737, Italian Ministry of Research and University (PRIN 2017WC8499) and Italian Ministry of Health (Research project on CAR T cells for hematological malignancies and solid tumors).
Publisher Copyright:
© Copyright © 2021 Guerrouahen, Elnaggar, Al-Mohannadi, Kizhakayil, Bonini, Benjamin, Brentjens, Buchholz, Casorati, Ferrone, Locke, Martin, Schambach, Turtle, Veys, van der Vliet, Maccalli and The EICCI Faculty Group.
PY - 2021/1/14
Y1 - 2021/1/14
N2 - The progress in the isolation and characterization of tumor antigen (TA)-specific T lymphocytes and in the genetic modification of immune cells allowed the clinical development of adoptive cell therapy (ACT). Several clinical studies highlighted the striking clinical activity of T cells engineered to express either Chimeric Antigen (CAR) or T Cell (TCR) Receptors to target molecularly defined antigens expressed on tumor cells. The breakthrough of immunotherapy is represented by the approval of CAR-T cells specific for advanced or refractory CD19+ B cell malignancies by both the Food and Drug Administration (FDA) and the European Medicinal Agency (EMA). Moreover, advances in the manufacturing and gene editing of engineered immune cells contributed to the selection of drug products with desired phenotype, refined specificity and decreased toxicity. An important step toward the optimization of CAR-T cell therapy is the development of “off-the shelf” T cell products that allow to reduce the complexity and the costs of the manufacturing and to render these drugs available for a broad number of cancer patients. The Engineered Immune Cells in Cancer Immunotherapy (EICCI) workshop hosted in Doha, Qatar, renowned experts, from both academia and industry, to present and discuss the progress on both pre-clinical and clinical development of genetically modified immune cells, including advances in the “off-the-shelf” manufacturing. These experts have addressed also organizational needs and hurdles for the clinical grade production and application of these biological drugs.
AB - The progress in the isolation and characterization of tumor antigen (TA)-specific T lymphocytes and in the genetic modification of immune cells allowed the clinical development of adoptive cell therapy (ACT). Several clinical studies highlighted the striking clinical activity of T cells engineered to express either Chimeric Antigen (CAR) or T Cell (TCR) Receptors to target molecularly defined antigens expressed on tumor cells. The breakthrough of immunotherapy is represented by the approval of CAR-T cells specific for advanced or refractory CD19+ B cell malignancies by both the Food and Drug Administration (FDA) and the European Medicinal Agency (EMA). Moreover, advances in the manufacturing and gene editing of engineered immune cells contributed to the selection of drug products with desired phenotype, refined specificity and decreased toxicity. An important step toward the optimization of CAR-T cell therapy is the development of “off-the shelf” T cell products that allow to reduce the complexity and the costs of the manufacturing and to render these drugs available for a broad number of cancer patients. The Engineered Immune Cells in Cancer Immunotherapy (EICCI) workshop hosted in Doha, Qatar, renowned experts, from both academia and industry, to present and discuss the progress on both pre-clinical and clinical development of genetically modified immune cells, including advances in the “off-the-shelf” manufacturing. These experts have addressed also organizational needs and hurdles for the clinical grade production and application of these biological drugs.
KW - CAR-NK cells
KW - CAR-T cells
KW - TCR engineered lymphocytes
KW - cancer
KW - clinical trial
KW - immunotherapy
KW - monoclonal antibody
KW - off-the-shelf development
UR - http://www.scopus.com/inward/record.url?scp=85100073925&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100073925&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2020.589381
DO - 10.3389/fimmu.2020.589381
M3 - Review article
C2 - 33584653
AN - SCOPUS:85100073925
SN - 1664-3224
VL - 11
JO - Frontiers in immunology
JF - Frontiers in immunology
M1 - 589381
ER -